Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptorJENA, Bipulendu; DOTTI, Gianpietro; COOPER, Laurence J. N et al.Blood. 2010, Vol 116, Num 7, pp 1035-1044, issn 0006-4971, 10 p.Article

Generation of adenosine A₃ receptor functionally humanized mice for the evaluation of the human antagonistsYAMANO, Kazuya; INOUE, Miho; MASAKI, Shigehiro et al.Biochemical pharmacology. 2005, Vol 71, Num 3, pp 294-306, issn 0006-2952, 13 p.Article

A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cellsKHALEGHI, Sepideh; RAHBARIZADEH, Fatemeh; AHMADVAND, Davoud et al.International journal of hematology. 2012, Vol 95, Num 4, pp 434-444, issn 0925-5710, 11 p.Article

Type III interferon induces apoptosis in human lung cancer cellsWEI LI; XI AOJIE HUANG; ZHUOMING LIU et al.Oncology reports. 2012, Vol 28, Num 3, pp 1117-1125, issn 1021-335X, 9 p.Article

Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies : Recent Progress in Gene TherapyDAVILA, Marco L; BOUHASSIRA, Diana C. G; PARK, Jae H et al.International journal of hematology. 2014, Vol 99, Num 4, pp 361-371, issn 0925-5710, 11 p.Article

Generation of CD19-chimeric antigen receptor modified CD8⁺ T cells derived from virus-specific central memory T cellsTERAKURA, Seitaro; YAMAMOTO, Tori N; GARDNER, Rebecca A et al.Blood. 2012, Vol 119, Num 1, pp 72-82, issn 0006-4971, 11 p.Article

Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a Recombinant DNA Advisory Committee Symposium Held June 15, 2010ERTL, Hildegund C. J; ZAIA, John; ROSENBERG, Steven A et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 9, pp 3175-3181, issn 0008-5472, 7 p.Article

Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptorTONG ZHANG; BARBER, Amorette; SENTMAN, Charles L et al.Cancer research (Baltimore). 2006, Vol 66, Num 11, pp 5927-5933, issn 0008-5472, 7 p.Article

Engineering T cells for cancer therapyMANSOOR, W; GILHAM, D. E; THISTLETHWAITE, F. C et al.British journal of cancer. 2005, Vol 93, Num 10, pp 1085-1091, issn 0007-0920, 7 p.Article

Reversal of antigen-dependent signaling by two mutations in antibody/receptor chimera: implication of inverse agonism in cytokine receptor superfamilyKAWAHARA, Masahiro; ISHII, Shinya; TSUMOTO, Kouhei et al.Biochemical pharmacology. 2004, Vol 68, Num 3, pp 539-548, issn 0006-2952, 10 p.Article

A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor CellsCHANG, Yu-Hsiang; CONNOLLY, John; SHIMASAKI, Noriko et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 6, pp 1777-1786, issn 0008-5472, 10 p.Article

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptorHUDECEK, Michael; SCHMITT, Thomas M; WOOD, Brent et al.Blood. 2010, Vol 116, Num 22, pp 4532-4541, issn 0006-4971, 10 p.Article

Simple and highly sensitive assay system for TNFR2-mediated soluble-and transmembrane-TNF activityABE, Yasuhiro; YOSHIKAWA, Tomoaki; YOSHIOKA, Yasuo et al.Journal of immunological methods. 2008, Vol 335, Num 1-2, pp 71-78, issn 0022-1759, 8 p.Article

Chimeric Antigen Receptor―Modified T Cells for Acute Lymphoid LeukemiaGRUPP, Stephan A; KALOS, Michael; MILONE, Michael C et al.The New England journal of medicine. 2013, Vol 368, Num 16, pp 1509-1518, issn 0028-4793, 10 p.Article

Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid LeukemiaPORTER, David L; LEVINE, Bruce L; KALOS, Michael et al.The New England journal of medicine. 2011, Vol 365, Num 8, pp 725-733, issn 0028-4793, 9 p.Article

Antigen-mediated migration of murine pro-B Ba/F3 cells via an antibody/receptor chimeraKAWAHARA, Masahiro; SHIMO, Yusuke; SOGO, Takahiro et al.Journal of biotechnology. 2008, Vol 133, Num 1, pp 154-161, issn 0168-1656, 8 p.Article

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cellsKOWOLIK, Claudia M; TOPP, Max S; GONZALEZ, Sergio et al.Cancer research (Baltimore). 2006, Vol 66, Num 22, pp 10995-11004, issn 0008-5472, 10 p.Article

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCRTORIKAI, Hiroki; REIK, Andreas; LEE, Dean A et al.Blood. 2012, Vol 119, Num 24, pp 5697-5705, issn 0006-4971, 9 p.Article

The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer : Progress in Pediatric CancerLEE, Daniel W; BARRETT, David M; MACKALL, Crystal et al.Clinical cancer research (Print). 2012, Vol 18, Num 10, pp 2780-2790, issn 1078-0432, 11 p.Article

Selective expansion of genetically modified T cells using an antibody/interleukin-2 receptor chimeraSOGO, Takahiro; KAWAHARA, Masahiro; TSUMOTO, Kouhei et al.Journal of immunological methods. 2008, Vol 337, Num 1, pp 16-23, issn 0022-1759, 8 p.Article

Growth control of hybridoma cells with an artificially induced EpoR-gp130 heterodimerKAWAHARA, Masahiro; OGO, Yuko; TSUMOTO, Kouhei et al.Cytotechnology (Dordrecht). 2006, Vol 52, Num 3, pp 171-179, issn 0920-9069, 9 p.Conference Paper

Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphomaMIHARA, Keichiro; YANAGIHARA, Kazuyoshi; KIMURA, Akiro et al.British journal of haematology. 2010, Vol 151, Num 1, pp 37-46, issn 0007-1048, 10 p.Article

Activated T-cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin LymphomaMIHARA, Keichiro; YANAGIHARA, Kazuyoshi; TAKIGAHIRA, Misato et al.Journal of immunotherapy (1997). 2009, Vol 32, Num 7, pp 737-743, issn 1524-9557, 7 p.Article

Eradication of Established B-cell Lymphoma by CD19-specific Murine T Cells is Dependent on Host Lymphopenic Environment and Can be Mediated by CD4⁺ and CD8⁺ T CellsCHEADLE, Eleanor J; HAWKINS, Robert E; BATHA, Hayley et al.Journal of immunotherapy (1997). 2009, Vol 32, Num 3, pp 207-218, issn 1524-9557, 12 p.Article

The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphomaCHEADLE, Eleanor J; GILHAM, David E; HAWKINS, Robert E et al.British journal of haematology. 2008, Vol 142, Num 1, pp 65-68, issn 0007-1048, 4 p.Article